Why the study?
Does TCV-116 inhibit the pressor action of exogenous Ang II in healthy male volunteers?
Population
27 healthy male volunteers
Comparison
TCV-116 for 8 days, with repeated bolus… vs Placebo (for the 1, 2, and 4 mg dose groups)
Design
RCT, Double-blind for placebo and 1, 2, 4 mg groups; single-blind for 8 mg group
Follow-up
8 days
Authors
Loading...
TCV-116 delivers potent, long-lasting Ang II blockade in humans; confirms oral AT1 antagonism and supports hypertension trials.
Does TCV-116 inhibit the pressor action of exogenous Ang II in healthy male volunteers?
TCV-116 is a potent, orally active, and long-lasting angiotensin II receptor antagonist that effectively inhibits Ang II-induced pressor responses in healthy men.
Delacrétaz et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: